Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Feb 20, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
7
2023 to 2026
Breakthrough
0
Accelerated
0
Priority review
1
Orphan
0
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 4 | 0 |
| 2024 | 2 | 0 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
7 approvals
Newest first. Hover a badge for what it means.
- Bysanti (Milsaperidone) · Vanda Pharms INCFeb 20, 2026
To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder
- Cobenfy (Trospium Chloride, Xanomeline Tartrate) · Bristol-MyersSep 26, 2024
To treat schizophrenia
- Opipza (Aripiprazole) · Xiamen Lp Pharm COJul 22, 2024Original approval · NDA 216655Approval letter
- Exxua (Gepirone Hydrochloride) · Fabre KramerSep 22, 2023
To treat major depressive disorder
- Zurzuvae (Zuranolone) · BiogenAug 4, 2023
To treat postpartum depression
- Uzedy (Risperidone) · TevaApr 28, 2023Original approval · NDA 213586Approval letter
- Abilify Asimtufii (Aripiprazole) · OtsukaApr 27, 2023Original approval · NDA 217006Approval letter
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.